Cite

    James F. Donohue et al.. “Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease.” Respiratory medicine, vol. 153, 2019, pp. 38–43. http://access.bl.uk/ark:/81055/vdc_100086506602.0x00002d